Rapamycin Ameliorates Experimental Autoimmune Uveoretinitis By Inhibiting Thl/Th2/Th17 Cells And Upregulating Cd4+Cd25+Foxp3 Regulatory T Cells

x j ren
DOI: https://doi.org/10.3980/j.issn.2222-3959.2015.04.03
IF: 1.645
2015-01-01
International Journal of Ophthalmology
Abstract:AIM: To determine the effects of rapamycin on experimental autoimmune uveoretinitis (EAU) and investigate of role of rapamycin on T cell subsets in the disease.METHODS: EAU was induced in rats using peptides 1169 to 1191 of the interphotoreceptor binding protein (IRBP). Rapamycin (0.2 mg/kg/d) was administrated by intraperitoneal injection for a consecutive 7d after immunization. Th1/Th2/Th17 cytokines, TGF-beta 1, and IL-6 produced by lymphocyteswere measured by ELISA, while Th17 cells and CD4 +CD25 + regulatory T cells (Tregs) from rat spleen were detected by flow cytometry.RESULTS: Intraperitoneal treatment immediately after immunization dramatically ameliorated the clinical course of EAU. Clinical responses were associated with reduced retinal inflammatory cell infiltration and tissue destruction. Rapamycin induced suppression of Th1/Th2/Th17 cytokines, including IFN-gamma, IL-2, IL-17, IL-4, and IL-10 release from T lymphocytes of EAU rats, in vitro. Rapamycin also significantly increased TGF -beta 1 production but had no effect on IL-6 productionof T lymphocytes from EAU rats in vitro. Furthermore, rapamycin decreased the ratio of Th17 cells/CD4+T cells and upregulated Tregs in EAU, as detected by flow cytometry. "CONCLUSION: Rapamycin effectively interferes with T cell mediated autoimmune uveitis by inhibiting antigen specific T cell functions and enhancing Tregs in EAU. Rapamycin is a promising new alternative as an adjunct corticosteroid sparing agent for treating uveitis.
What problem does this paper attempt to address?